BioCryst Pharmaceuticals (BCRX) Superinvestor holders
19 of the superinvestors we track hold BioCryst Pharmaceuticals (BCRX) in their latest 13F filings, $195M in total.
Summary
The largest holder is Two Sigma (Two Sigma Investments), with $68M, 0.1% of the portfolio.
In their latest quarter: 4 opened a new position, 8 added, 7 trimmed.
Who holds it
Each investor's latest 13F filing, largest stake first. What a 13F shows.
| Investor | Last change | Shares | Value | % of portfolio | Filed for |
|---|---|---|---|---|---|
| Two Sigma Two Sigma Investments |
Added | 6,775,349 | $68M | 0.1% | Q2 2026 |
| Jim Simons Renaissance Technologies |
Added | 2,530,290 | $25M | 0.0% | Q2 2026 |
| Cliff Asness AQR Capital Management |
Added | 2,214,302 | $22M | 0.0% | Q2 2026 |
| Ken Fisher Fisher Investments |
Trimmed | 2,448,598 | $20M | 0.0% | Q3 2026 |
| Wilmot Harkey Nantahala Capital Management |
Trimmed | 1,901,160 | $19M | 1.2% | Q2 2026 |
| Louis Bacon Moore Capital Management |
New position | 848,336 | $8M | 0.2% | Q2 2026 |
| Man Group Man Group plc |
Trimmed | 732,867 | $7M | 0.0% | Q2 2026 |
| Acadian Acadian Asset Management |
Added | 619,967 | $5M | 0.0% | Q3 2026 |
| Ray Dalio Bridgewater Associates |
Trimmed | 491,057 | $5M | 0.0% | Q2 2026 |
| David Shaw D. E. Shaw & Co. |
Added | 408,529 | $4M | 0.0% | Q2 2026 |
| Steve Cohen Point72 Asset Management |
New position | 260,917 | $3M | 0.0% | Q2 2026 |
| Paul Marshall Marshall Wace |
Added | 252,764 | $3M | 0.0% | Q2 2026 |
| Paul Tudor Jones Tudor Investment Corp |
New position | 195,128 | $2M | 0.0% | Q2 2026 |
| Joel Greenblatt Gotham Asset Management |
Trimmed | 156,421 | $2M | 0.0% | Q2 2026 |
| Alan Howard Brevan Howard |
Added | 96,574 | $965,740 | 0.0% | Q2 2026 |
| Alger Fred Alger Management |
Trimmed | 64,112 | $641,120 | 0.0% | Q2 2026 |
| Peter Muller PDT Partners |
Trimmed | 24,489 | $244,890 | 0.0% | Q2 2026 |
| Ensign Peak Ensign Peak Advisors |
Added | 17,450 | $174,500 | 0.0% | Q2 2026 |
| Alec Litowitz Magnetar Capital |
New position | 16,172 | $161,720 | 0.0% | Q2 2026 |
Holders by quarter
| Quarter | Superinvestors holding it |
|---|---|
| Q2 2026 | 19 |
| Q1 2026 | 16 |
| Q4 2025 | 18 |
| Q3 2025 | 21 |
| Q2 2025 | 18 |
| Q1 2025 | 17 |
| Q4 2024 | 15 |
| Q3 2024 | 16 |
Questions about BioCryst Pharmaceuticals
Which superinvestors own BioCryst Pharmaceuticals?
19 of the superinvestors we track hold BioCryst Pharmaceuticals (BCRX) in their latest 13F filings, $195M in total. Two Sigma, Jim Simons, Cliff Asness, Ken Fisher, Wilmot Harkey, Louis Bacon.
Who is the largest superinvestor holder of BCRX?
The largest holder is Two Sigma (Two Sigma Investments), with $68M, 0.1% of the portfolio.
From BioCryst Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.